FDA Advisory Committee (AdCom) Meetings: How the Vote Moves a Stock
An FDA advisory committee, or AdCom, is a panel of outside experts that reviews a drug's data in a public meeting and votes on whether its benefits outweigh its risks. The vote is not binding, but the FDA usually follows it. From 2010 to 2021, approval followed 97% of positive votes on new drugs, and rejection followed 67% of negative votes.
What happens at an FDA advisory committee meeting
A few days before the meeting, the FDA posts its briefing documents online. Investors read these closely, because they show what worries the FDA reviewers. The stock often moves on the briefing documents before anyone has voted.
On the day, the company presents, FDA staff present, the public can speak, and the panel discusses. Then the members vote on questions the FDA has written, usually some version of "do the benefits outweigh the risks?" The PDUFA date normally comes weeks or months later.
How often does the FDA follow the AdCom vote?
Most of the time. A study in JAMA Health Forum looked at FDA advisory committee votes from 2010 to 2021. The FDA's action matched the vote 88% of the time overall. For new drugs, approval followed 142 of 147 positive votes (97%). Rejection followed 40 of 60 negative votes (67%).
Read those two numbers together. A yes vote is close to a green light. A no vote is a serious problem, but one in three drugs with a negative vote still got approved. The FDA also calls these meetings less often than it used to, so many drugs now reach their PDUFA date with no AdCom at all.
Real example: UroGen, approved after a no vote
In the days before the meeting the stock dropped from $9.85 to $7.31 (May 16), before the panel had even voted. After the 4 to 5 vote against, it slid to $3.93. The FDA approved the drug anyway. This is the one in three case, and it shows why a no vote is not the end of the story.
How investors approach an AdCom
- Watch the briefing documents. They usually come out two business days before the meeting and often move the stock more than the vote.
- Read the questions, not just the vote. A panel can vote yes on efficacy and still raise safety concerns that shape the label.
- Size for a binary event. AdCom days can move small biotechs 30% or more either way.
- Check the cash. If a no vote leads to a CRL, can the company afford another trial?
See it live: Upcoming FDA decisions and advisory committee dates, with cash, insider activity and short interest in the same row.
Open the FDA Calendar →Watch the video walkthrough
Prefer YouTube? Watch it there.
Frequently asked questions
It is a panel of outside experts, such as doctors, statisticians and patient representatives, that reviews a drug application in a public meeting and votes on questions the FDA asks. The vote is advice; the FDA makes the final decision.
No. The FDA usually follows it: from 2010 to 2021 its action matched the vote 88% of the time. But it has approved drugs after negative votes and rejected drugs after positive ones.
Usually two business days before the meeting, on the FDA's website. They often move the stock before the vote.
No. The FDA decides when to hold one, often for new types of drugs or when the data raises hard questions. It has called these meetings less often in recent years.
Usually weeks to a few months, on or before the drug's PDUFA date.
Educational content only. Not financial advice. Past results don't predict future ones.